# Zim Laboratories (NSE: ZIMLAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ZIMLAB · Pivot · prices to 22 Oct 2026

Zim Laboratories (NSE: ZIMLAB) closed at ₹133.50 on 22 Oct 2026, up 2.30% on the day. With a market capitalisation of ₹715 Cr, it ranks 1616th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 112.2× trailing earnings, against a return on equity of 2.0% in FY26. Over the past year the share price has risen 92.4%. Its 52-week range is ₹59.31 (30 Mar 2026) to ₹159.81 (12 Oct 2026); the last close is 16.5% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹94 Cr (+31.2% year on year) and net profit −₹4 Cr, on a consolidated basis. Promoters held 30.36% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹133.50 |
| Market cap | ₹715 Cr |
| P/E (trailing) | 112.2 |
| ROE | 2.0% (FY26) |
| ROCE | 6.1% (FY26) |
| Debt to equity | 0.42 |
| 52-week high | ₹159.81 (12 Oct 2026) |
| 52-week low | ₹59.31 (30 Mar 2026) |
| 1-year return | +92.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹94 Cr | +31.2% | −₹4 Cr | — | −₹0.75 |
| Q4 FY26 | ₹105 Cr | −3.2% | ₹4 Cr | −23.4% | ₹0.76 |
| Q3 FY26 | ₹109 Cr | +12.8% | ₹4 Cr | +10.0% | ₹0.90 |
| Q2 FY26 | ₹89 Cr | −3.7% | −₹0 Cr | −117.6% | −₹0.09 |
| Q1 FY26 | ₹72 Cr | −12.3% | −₹2 Cr | −307.8% | −₹0.38 |
| Q4 FY25 | ₹109 Cr | −7.7% | ₹5 Cr | −39.7% | ₹1.01 |
| Q3 FY25 | ₹96 Cr | +0.0% | ₹4 Cr | −16.3% | ₹0.82 |
| Q2 FY25 | ₹92 Cr | +7.4% | ₹2 Cr | −42.7% | ₹0.49 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹379 Cr | ₹12 Cr |
| FY24 | ₹367 Cr | ₹17 Cr |
| FY23 | ₹399 Cr | ₹24 Cr |
| FY22 | ₹333 Cr | ₹15 Cr |
| FY21 | ₹307 Cr | ₹7 Cr |
| FY20 | ₹278 Cr | ₹3 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 30.36%
- Foreign institutions: 0.03%
- Domestic institutions: 1.33%
- Non-institutions: 68.28%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Kilitch Drugs (India)](https://app.pivotnow.in/stock/KILITCH) | ₹215.00 | ₹752 Cr | 24.2 | — |
| [Vikram Thermo](https://app.pivotnow.in/stock/VIKRAMTH) | — | ₹728 Cr | — | — |
| [Valiant Laboratories](https://app.pivotnow.in/stock/VALIANTLAB) | ₹131.05 | ₹712 Cr | — | — |
| [Amanta Healthcare](https://app.pivotnow.in/stock/AMANTA) | ₹182.55 | ₹709 Cr | 42.2 | — |
| [Gaudium IVF and Women Health](https://app.pivotnow.in/stock/GAUDIUMIVF) | ₹95.11 | ₹692 Cr | 24.3 | — |
| [Wanbury](https://app.pivotnow.in/stock/WANBURY) | ₹185.66 | ₹649 Cr | 9.6 | — |

## Questions and answers

### What is the share price of Zim Laboratories today?

Zim Laboratories (NSE: ZIMLAB) last closed at ₹133.50 on 22 Oct 2026. Its 52-week high is ₹159.81 and its 52-week low is ₹59.31.

### What is the market cap of Zim Laboratories?

Zim Laboratories' market capitalisation is ₹715 Cr (₹715 Cr) at the 22 Oct 2026 close, ranking 1616th among the NSE companies Pivot tracks.

### What is the P/E ratio of Zim Laboratories?

Zim Laboratories trades at a trailing P/E of 112.2. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 24.3.

### What is the ROE and ROCE of Zim Laboratories?

Return on equity was 2.0% in FY26 and return on capital employed was 6.1% in FY26 (consolidated figures).

### Is Zim Laboratories a debt-free company?

No. Zim Laboratories' debt-to-equity ratio was 0.42 in FY26, with total debt of ₹42 Cr.

### What were Zim Laboratories' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Zim Laboratories reported revenue of ₹94 Cr, +31.2% year on year, and net profit of −₹4 Cr.

### How has Zim Laboratories stock performed over the last year?

Zim Laboratories' share price has risen 92.4% over the past year, +14.6% over three months and −1.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Zim Laboratories?

As of 30 Jun 2026: promoters 30.36%, foreign institutions 0.03%, domestic institutions 1.33%, non-institutions 68.28%.

### Who are Zim Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Zim Laboratories by market cap are Kilitch Drugs (India), Vikram Thermo, Valiant Laboratories, Amanta Healthcare, Gaudium IVF and Women Health and Wanbury.

### Is Zim Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Zim Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ZIMLAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.